<- Go Home
Silverback Therapeutics, Inc.
As of November 8, 2022, Silverback Therapeutics, Inc. was acquired by ARS Pharmaceuticals, Inc., in a reverse merger transaction. Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Market Cap
$210.6M
Volume
381.4K
Cash and Equivalents
$203.2M
EBITDA
-$78.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$10.8M
Profit Margin
N/A
52 Week High
$8.97
52 Week Low
$2.80
Dividend
N/A
Price / Book Value
0.79
Price / Earnings
-2.41
Price / Tangible Book Value
0.79
Enterprise Value
-$55.8M
Enterprise Value / EBITDA
0.73
Operating Income
-$79.1M
Return on Equity
28.50%
Return on Assets
-15.86
Cash and Short Term Investments
$266.6M
Debt
$215.0K
Equity
$267.1M
Revenue
N/A
Unlevered FCF
-$39.6M
Sector
Biotechnology
Category
N/A